Cumulus Neuroscience announced new research showing that a three-minute, non-invasive EEG test known as Fastball can reliably detect early memory impairment in individuals with mild cognitive impairment (MCI), a condition often preceding Alzheimer’s disease, according to the company. The study, conducted by researchers at the University of Bath and the University of Bristol, demonstrated for the first time that Fastball EEG can deliver consistent results in real-world settings, including patients’ homes.
Cumulus Neuroscience said it is developing AccelADx®, a scalable screening tool built on Fastball technology, which is now being deployed in two large grant-funded trials enrolling 1,000 participants in the UK and another 1,000 across the US, Canada, and Europe. The company claims that enabling early screening outside clinical environments is a critical step toward broader Alzheimer’s detection and intervention, especially given that treatments such as donanemab and lecanemab are most effective at early stages.
The study, published in Brain Communications, was led by Dr George Stothart of the University of Bath, who the company said highlighted the need for accessible, objective tools to detect cognitive decline years earlier than current methods allow. Funded by the Academy of Medical Sciences and supported by dementia charity BRACE, the research represents a cost-effective, portable option for early memory impairment detection.
